Globally, diabetes kidney disease (DKD) caused more than 425,000 deaths in 2017 and led to 35% of deaths from chronic kidney disease.1 Further, type 2 diabetes mellitus (T2DM) represents a major risk factor for cardiovascular (CV) morbidity and mortality.2 This indicates that more effective antihyperglycemic agents are urgently needed to reduce the burden of DKD and CV morbidity and mortality. In this regard, Boehringer Ingelheim India and Docplexus have organized a Multi-Specialty Panel Discussion on 28th August 2020 from 03:00 PM IST onwards. In this webinar, the expert panel will discuss comprehensive details regarding the role of SGLT-2i + DPP-4i combination therapy in the management of cardio-renal metabolic risk.
We invite you to share your questions which will be answered by the experts at the end of the session. Reference: 1. Cai Y, et al., Biomedicine & Pharmacotherapy.…